Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $26.94M
• Dividend Yield: N/A
• Average Volume (3M): 198.71K
• Price to Earnings (P/E): 41.3
• Beta (1Y): -0.26
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: General
• Sector Strength: N/A
• Industry: Traditional Media
• EPS (TTM): 0.04
• Shares Outstanding: 2,131,595
• 10 Day Avg. Volume: 49,113
• 30 Day Avg. Volume: 198,710
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.09
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Haoxi Health Technology Limited exhibits strong revenue growth and improved financial stability, driving a positive outlook. However, challenges in cash flow management, overvaluation concerns, and technical indicators pointing to bearish momentum weigh down the score. The stock's high P/E ratio and lack of dividends highlight significant investor expectations, which may not be supported by current financial metrics.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited Class A (HAO) is a company operating in the healthcare technology sector, specializing in innovative health solutions. The company focuses on developing and providing digital health platforms, health monitoring devices, and wellness applications aimed at improving patient care and health management for individuals and healthcare providers.

How the Company Makes Money

Haoxi Health Technology Limited generates revenue primarily through the sale of its digital health platforms and health monitoring devices to healthcare providers, hospitals, and individual consumers. The company also earns income from subscription fees for its wellness applications, which offer premium features and personalized health insights. In addition, Haoxi Health Technology Limited may engage in strategic partnerships with healthcare organizations to expand its market reach and enhance its service offerings. These partnerships can lead to increased sales and cross-promotional opportunities, further contributing to the company's earnings.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited displays significant revenue growth and profitability turnaround, with improving equity position and low leverage. However, challenges remain in terms of cash flow generation and profit margins. Overall, the company is on a positive trajectory but needs to enhance its cash flow management and profitability to sustain long-term growth.

Income Statement

Haoxi Health Technology Limited shows strong revenue growth with a substantial increase from $28.2M in 2023 to $48.5M in 2024, marking a growth rate of 71.88%. The gross profit margin in 2024 stands at 5.67%, indicating an improvement over previous years but still relatively low. The net profit margin for 2024 is 2.66%, demonstrating profitability but with room for improvement. EBIT and EBITDA margins are 3.54% and 3.68%, respectively, showing stability in earnings.

Balance Sheet

The company exhibits a solid equity position with a positive stockholders' equity of $11.27M in 2024, a significant turnaround from negative equity in earlier years. However, the debt-to-equity ratio is 0.11, indicating low leverage but also reflecting a cautious approach. The equity ratio is relatively strong at 72.69%, showcasing financial stability, though the overall asset base remains modest.

Cash Flow

Cash flow performance is mixed, with negative free cash flow of -$802,943 in 2024, although showing improvement from the previous year. The operating cash flow to net income ratio is -0.58, suggesting that operating activities are not yet fully supporting net income generation. Despite this, the company has improved its financing cash flow, indicating potential for future investments.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement		Total Revenue
48.52M	28.23M	16.16M	12.85M
	Gross Profit
2.75M	2.06M	648.72K	605.58K
	EBIT
1.72M	1.20M	268.77K	330.55K
	EBITDA
1.79M	1.22M	271.77K	330.96K
	Net Income Common Stockholders
1.29M	969.75K	244.59K	304.06K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.66M	1.20M	293.51K	55.89K
	Total Assets
15.51M	4.46M	542.99K	2.81M
	Total Debt
1.20M	897.61K	505.40K	1.15M
	Net Debt
-5.45M	-305.59K	211.89K	1.09M
	Total Liabilities
4.23M	2.90M	2.01M	4.74M
	Stockholders Equity
11.27M	1.57M	-1.47M	-1.93M
Cash Flow		Free Cash Flow
-802.94K	-917.63K	―	2.65M
	Operating Cash Flow
-747.58K	-872.13K	-675.36K	2.65M
	Investing Cash Flow
-3.13M	-45.50K	―	―
	Financing Cash Flow
9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.82, below the 50-day MA of 2.58, and below the 200-day MA of 51.76, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 32.91 is Neutral, neither overbought nor oversold. The STOCH value of 28.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	79 Outperform	$11.58B	61.60	21.24%	―	17.47%	49.87%
HIMS	73 Outperform	$7.71B	64.90	30.71%	―	69.33%	―
Sector *	54 Neutral	$4.27B	-16.36	-11.71%	4.83%	31.84%	-53.69%
HAO	52 Neutral	$26.94M	41.27	11.46%	―	―	―
CLOV	46 Neutral	$1.72B	―	-14.75%	―	-32.45%	80.24%
TDOC	45 Neutral	$1.56B	―	-52.46%	―	-1.26%	-338.56%
AMWL	43 Neutral	$127.07M	―	-54.13%	―	-1.81%	70.88%